Selective inhibition of latent TGFβ1, the predominantly expressed TGFβ isoform in cancers, is efficient in potentiating the anti-cancer immune response in a murine model of refractory bladder cancer (24) but yet to be evaluated clinically. Here, TGFB1 is linked to urinary bladder cancer.